Wei Hua1, Sen Wang2, Xi Wang1, Ying Shao1, Yali Wang1, Jiangzhu Ye1, Bin Su1, Taiyi Jiang1, Tong Zhang1, Hao Wu1, An Liu1, Qunhui Li1, Supriya D Mahajan3, Zaicun Li1, Lijun Sun1, Lili Dai1. 1. Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China. 2. Department of Infectious Diseases, Institute of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. 3. Division of Allergy, Immunology and Rheumatology, Department of Medicine, Clinical & Translational Research Center, University at Buffalo, Buffalo, NY, United States.
Abstract
Background: Efavirenz (EFV) is widely used in antiretroviral therapy (ART), but the incidence and risk factors of neuropsychiatric adverse events (NPAEs) after EFV treatment have rarely been studied in Chinese ART naïve patients. Methods: This prospective cohort study assessed HIV-infected patients initiating antiretroviral treatment with EFV to determine prevalence of and factors associated with NPAEs over a 12-month follow-up period using the Hospital Anxiety and Depression Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI). Results: A total of 546 patients were enrolled. Prevalence of anxiety, depression, and sleep disturbances at baseline were 30.4, 22.7, and 68.1%, respectively. Six patients discontinued treatment due to drug related NPAEs. Treatment was associated with improvements in HADS-A, HADS-D, and PSQI scores over the 12-month follow-up, and the frequencies of patients with anxiety, depression, and sleep disturbances significantly decreased after 12 months. Abnormal baseline HADS-A, HADS-D, and PSQI scores and other factors, including high school education or lower income, unemployment, divorce, and WHO III/IV stages, were associated with severe neuropsychiatric disorders over the 12 months. Conclusions: These findings suggested EFV discontinuation due to NAPEs was low, and the HADS-A, HADS-D, and PSQI scores after 12 months of EFV treatment were associated with several risk factors. The clinicians should keep in mind and routinely screen for the risk factors associated with neuropsychiatric disorders in HIV-infected patients.
Background: Efavirenz (EFV) is widely used in antiretroviral therapy (ART), but the incidence and risk factors of neuropsychiatric adverse events (NPAEs) after EFV treatment have rarely been studied in Chinese ART naïve patients. Methods: This prospective cohort study assessed HIV-infectedpatients initiating antiretroviral treatment with EFV to determine prevalence of and factors associated with NPAEs over a 12-month follow-up period using the Hospital Anxiety and Depression Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI). Results: A total of 546 patients were enrolled. Prevalence of anxiety, depression, and sleep disturbances at baseline were 30.4, 22.7, and 68.1%, respectively. Six patients discontinued treatment due to drug related NPAEs. Treatment was associated with improvements in HADS-A, HADS-D, and PSQI scores over the 12-month follow-up, and the frequencies of patients with anxiety, depression, and sleep disturbances significantly decreased after 12 months. Abnormal baseline HADS-A, HADS-D, and PSQI scores and other factors, including high school education or lower income, unemployment, divorce, and WHO III/IV stages, were associated with severe neuropsychiatric disorders over the 12 months. Conclusions: These findings suggested EFV discontinuation due to NAPEs was low, and the HADS-A, HADS-D, and PSQI scores after 12 months of EFV treatment were associated with several risk factors. The clinicians should keep in mind and routinely screen for the risk factors associated with neuropsychiatric disorders in HIV-infectedpatients.
Authors: P Yeni; D A Cooper; J P Aboulker; A G Babiker; D Carey; J H Darbyshire; M Floridia; P M Girard; R L Goodall; M H Hooker; A Mijch; V Meiffredy; B Salzberger Journal: Lancet Date: 2006-07-22 Impact factor: 79.321
Authors: Carmina R Fumaz; Albert Tuldrà; Ma José Ferrer; Roger Paredes; Anna Bonjoch; Toni Jou; Eugènia Negredo; Joan Romeu; Guillem Sirera; Cristina Tural; Bonaventura Clotet Journal: J Acquir Immune Defic Syndr Date: 2002-03-01 Impact factor: 3.731
Authors: Hans Jürgen von Giesen; Hubertus Köller; Dominique de Nocker; Bernhard A Haslinger; Gabriele Arendt Journal: HIV Clin Trials Date: 2003 Nov-Dec